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Effect of a 28-d treatment with L-796568, a novel 3-adrenergic
receptor agonist, on energy expenditure and body composition in
obese men1–3
Thomas M Larsen, Søren Toubro, Marleen A van Baak, Keith M Gottesdiener, Patrick Larson, Wim HM Saris, and Arne Astrup
ABSTRACT
Background: Stimulation of energy expenditure (EE) with selec-
tive thermogenic -adrenergic agonists may be a promising
approach for treating obesity.
Objective: We analyzed the effects of the highly selective human
3-adrenergic agonist L-796568 on 24-h EE, substrate oxidation,
and body composition in obese, weight-stable men.
Design: In this 2-center, double-blind, randomized, parallel-group
study, we measured 24-h EE before and after 28 d of treatment
with L-796568 (375 mg/d) or placebo during weight maintenance
(ie, without dietary intervention) in nondiabetic, nonsmoking men
aged 25–49 y with body mass index (in kg/m2) of 28–35 (n = 10
subjects per treatment group).
Results: The mean change in 24-h EE from before to after treat-
ment did not differ significantly between groups (92 ± 586 and
86 ± 512 kJ/24 h for the L-796568 and placebo groups, respec-
tively). The change in 24-h nonprotein respiratory quotient from
before to after treatment did not differ significantly between
groups (0.009 ± 0.021 and 0.009 ± 0.029, respectively). No
changes in glucose tolerance were observed, but triacylglycerol
concentrations decreased significantly with L-796568 treatment
compared with placebo (0.76 ± 0.76 and 0.42 ± 0.31 mmol/L,
respectively; P < 0.002). Overall, treatment-related changes in
body composition were not observed, but higher plasma L-796568
concentrations in the L-796568 group were associated with greater
decreases in fat mass (r = 0.69, P < 0.03).
Conclusions: Treatment with L-796568 for 28 d had no major
lipolytic or thermogenic effect but it lowered triacylglycerol con-
centrations. This lack of chronic effect on energy balance is
likely explained by insufficient recruitment of 3-responsive tis-
sues in humans, down-regulation of the 3-adrenergic receptor–
mediated effects with chronic dosing, or both. Am J Clin Nutr
2002;76:780–8.
KEY WORDS L-796568, 3-adrenergic receptor, 3-adrenergic
receptor agonist, 3 agonist, selectivity, energy expenditure,
lipolysis, respiratory quotient, indirect calorimetry, triacylglycerol,
obesity, obese men
INTRODUCTION
Several sympathomimetic agents are currently being used to
treat human obesity. These agents have potential anorectic and
thermogenic effects. However, the earlier use of nonselective
-adrenergic compounds was associated with adverse reactions
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such as tachycardia and tremor, which were attributable to 1
and 2 stimulation, respectively. The characterization of the
3-adrenergic receptor, mainly expressed in white adipose tissue
(WAT) and brown adipose tissue (BAT) (1, 2), evoked hope for a
new potential target in the pharmacologic treatment of obesity
and diabetes.
A marked thermogenic response to selective 3-adrenergic
receptor agonists was found in rodents (3, 4). When administered
over a period of weeks, these agonists induce weight loss and have
antidiabetic effects (3, 5). Furthermore, in addition to their ther-
mogenic effects, 3 agonists may promote fat loss by stimulating
fatty acid mobilization and, directly or indirectly, fat oxidation.
Studies of isolated human fat cells show lipolytic activity not
involving the 1 and 2 receptors (6, 7), and in vivo studies in
humans show lipolytic activity of the partial 3-adrenergic recep-
tor agonist CGP12177. This effect was not inhibited by the com-
bined 1 and 2 antagonist propranolol (8), and it was suggested
that the 3-adrenergic receptor may be responsible for a substan-
tial proportion of the lipolytic response to norepinephrine in
humans (9).
Among the 3 agonists tested in human clinical trials to date,
only the compound CL 316 243 has been recognized as weakly
potent, but selective, toward the human 3-adrenergic receptor
(10). In an 8-wk study in lean male subjects, this partial 3-adren-
ergic receptor agonist significantly increased insulin-stimulated
glucose disposal, fasting plasma fatty acid concentrations, and
24-h fat oxidation without any side effects mediated by 1 or 2;
however, no effects on energy expenditure or body weight were
observed.
L-796568, a novel 3-adrenergic receptor agonist for the human
3-adrenergic receptor, shows potency as a selective human 3
agonist when tested in cyclic AMP assays on Chinese hamster
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ovary cells transfected with the human 3-adrenergic receptor, and
the compound has an EC50 = 3.6 nmol/L (94% activation com-
pared with isoprenaline) with > 600-fold selectivity over the
human 1 and 2 receptors (11). A related 3 agonist that has sim-
ilar potency, L-755507, elicited a dose-dependent rise in meta-
bolic rate and lipolysis in rhesus monkeys; there was an 30%
increase in metabolic rate after intravenous bolus administration.
Chronic treatment with L-755507 was also accompanied by signi-
ficant increases in BAT and uncoupling protein 1 expression (12).
Human studies with L-796568 showed dose-dependent increases
in plasma glycerol and fatty acid concentrations (K Gottesdiener
and Merck & Co, unpublished observations, 1999). More impor-
tantly, in obese subjects who had fasted overnight, an 8% acute
thermogenic effect of a single 1000-mg dose of L-796568 was
found (13). The purpose of the present study was to test whether
this acute effect was maintained after 28 d of chronic treatment
with a dosing regimen (375 mg L-796568 once daily with food)
that was shown in a separate study to achieve plasma concentra-
tions of L-796568 similar to or higher than those achieved with a
single 1000-mg dose of L-796568 administered in the fasted state.
SUBJECTS AND METHODS
Study design
This double-blind, randomized, placebo-controlled, parallel-
group study was performed at 2 centers, Copenhagen and Maas-
tricht. A total of 20 male subjects were randomly assigned to
receive either 375 mg L-796568 or placebo, administered
once daily with breakfast. In each treatment group (placebo or
L-796568) there were 10 subjects (5 at each study site).
Energy expenditure (EE) and substrate oxidation rates were
determined with indirect calorimetry in respiration chambers on
a fixed physical-activity protocol. L-796568 was administered
at 0915 in the respiration chamber after a meal. The study con-
sisted of a baseline 24-h measurement (0915 to 0915) on day 0
(the day before treatment began) and a second measurement
obtained with an identical protocol on day 27. At the baseline
visit, the measurement was continued for 6 h after each subject
ingested his first dose of study medication to evaluate a possi-
ble acute effect of the compound. To investigate a possible drug
effect during particular periods of the day, the 24-h measurement
period (0915–0915) was divided into the following specific inter-
vals: sleep EE (0300–0600), basal metabolic rate (0730–0830),
daytime EE (0915–1315), exercise EE (1430–1445), and postdin-
ner EE (1915–2215).
Subjects
All subjects underwent a full physical examination with an
electrocardiogram, medical history, and routine hematology, bio-
chemistry, and urine screening tests. All were found to be in good
health (except for their obesity), without previous or current
endocrine, cardiovascular, or hepatic diseases. The subjects
reported no acute illnesses within the 2 wk immediately preced-
ing the start of the trial. None of the subjects were dieting or took
any medication regularly. They were all nonsmokers, aged 25–49 y,
with a body mass index (BMI; in kg/m2) between 28 and 35 and
stable weight (± 4 kg) for ≥ 3 mo before the study.
All subjects were carefully instructed to maintain their usual
dietary habits and body weight throughout the study. During the
28-d treatment period, the subjects consumed breakfasts with a
consistent composition each morning (1620 kJ, 30% of energy
from fat) to improve drug absorption (3-fold increase in area
under the curve when administered with food). They also avoided
excessive or strenuous physical activity and consumed no more
than 2 units (24 g) of alcohol and 4 cups of caffeinated bever-
ages/d. Alcohol intake was prohibited for 48 h before the respira-
tion chamber sessions. No other medication was allowed, and sub-
jects were instructed to report any additional medication used
during this period. The study was approved by the Ethics Com-
mittee of Frederiksberg and Copenhagen (Copenhagen site) and
the Medical Ethics Committee of Maastricht University (Maas-
tricht site). The subjects gave their written, informed consent
according to the Helsinki Declaration.
Anthropometry
Body weight was measured in light clothing on a decimal
scale on days 0, 7, 14, and 28 (in Copenhagen: Lindeltronic
8000, Lindells Inc, Kristianstad, Sweden; in Maastricht: Sauter
model D-7440, Sauter Inc, Ebingen, Germany). Body composi-
tion was estimated with dual-energy X-ray absorptiometry
within 7 d before treatment (prestudy) and again within 2 d after
the last treatment day (poststudy) (both sites: Lunar DPX-IQ;
General Electric, Madison, WI) and with the bioelectrical
impedance method (Copenhagen: Animeter; HTS-Engineering
Inc, Odense, Denmark and Maastrict: Hydra ECF/ICF model
4200; Xitron Technologies, San Diego). Heart rate and blood
pressure were measured with an automatic device (both sites:
Omron Automatic HEM-705CP; Omron Electronics GmbH,
Hamburg, Germany).
Indirect calorimetry
EE and substrate oxidation were measured in open-circuit
respiration chambers. At the Copenhagen site, the floor area
and volume were 6.5 m2 and 14.7 m3, respectively (14), whereas
at the Maastricht site, the floor area and volume were 7.0 m2
and 14.0 m3, respectively (15). The room temperature was
maintained at 24 C during the daytime and 18 C at night. The
oxygen and carbon dioxide exchange was determined by taking
measurements of the oxygen fraction (Copenhagen: Magnos
4G; Hartman and Braun, Frankfurt, Germany and Maastricht:
Magnos 6G, Hartman and Braun, in combination with OA184A;
Servomex, Crowborough, United Kingdom) and carbon diox-
ide fraction (both sites: Uras 3G; Hartman and Braun) at the
inlet and outlet of the chamber and from the flow of the out-
going air.
Urine was collected for a 24-h period on days 0 and 27 and also
during the 6-h period after the first dose. Urine samples were used
to estimate protein oxidation by assessing nitrogen excretion. Pro-
tein oxidation was calculated on the basis of the assumption that
6.25 g protein is combusted per gram of nitrogen excreted. Sub-
sequently, nonprotein oxygen and carbon dioxide exchanges were
calculated on the basis of the assumption that 0.952 L O2 is con-
sumed and 0.795 L CO2 is produced per gram of protein oxidized.
Carbohydrate and fat oxidation were then calculated by using the
constants published by Elia and Livesey (16).
Spontaneous physical activity in the respiration chambers was
assessed with 2 microwave radar instruments (Sisor Mini-Radar;
Static Input System SA, Lausanne, Switzerland) at the Copen-
hagen site and with an analogue ultrasound system (Aritech Advi-
sor DU160; Aritech BV, Roermond, Netherlands) at the Maas-
tricht site. The spontaneous physical activity scores were used to
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redefine the sleeping period if spontaneous physical activity
exceeded 2% during the prescribed period.
During the subjects’ stays in the respiration chamber, the activ-
ity protocols (ie, fixed meal times and sessions of physical
activity) were similar at the 2 sites. Two 15-min sessions of bicy-
cling at a work output of 75 W were included in the protocol at
1430 and 1630. To ensure adherence to the protocol, the subjects
were monitored constantly by a laboratory technician during the
daytime. To accustom the subjects to the respiration chamber envi-
ronment, they spent the night (Copenhagen) or at least some hours
(Maastricht) in the chamber before the experiments.
Diet
To achieve energy balance (defined as energy intake  EE,
± 0.5 MJ) during the stay in the respiration chamber, the appro-
priate dietary energy content (kJ/24 h) was individually calcu-
lated by using the subjects’ fat-free mass (FFM) in the following
equation: 136.1 kJ/kg  FFM in kg + 2154 kJ (17). FFM was
calculated with an algorithm determined on the basis of imped-
ance measurements in men (18). The dietary composition was
similar at the 2 study sites, providing an average of 50% of
energy from carbohydrates (range: 48.6–53.6%), 35% from fat
(32.2–35.6%), and 15% from protein (13.4–16.9%). The diet had
a calculated respiratory quotient (RQ; derived from the dietary
macronutrient composition) of 0.881, depending on the actual
energy intake. Dietary energy content and composition were cal-
culated by using BECEL dietary assessment software (Unilever,
Rotterdam, Netherlands) and the Dutch Food Composition
Table at the Maastricht site. At the Copenhagen site, we used
DANKOST dietary assessment software, version 2.0 (Danish
Catering Center Denmark). Both software programs use the
Atwater factors for metabolizable energy. Any food not con-
sumed by the subjects was reweighed and subtracted to calcu-
late actual energy and macronutrient intakes. A maximum of 2
cups tea or coffee was allowed during the respiratory chamber
measurements, and intake during the baseline measurement was
replicated during the second measurement.
Blood and urine sample collection
While the subjects were in a fasted state and resting, blood sam-
ples were obtained from a forearm vein; this was done before sub-
jects entered the chamber on day 0 and after they left the chamber
on day 28. The blood was analyzed for norepinephrine, epineph-
rine, fatty acids, triacylglycerol, glycerol, lactate, ketones
(-hydroxybutyrate), total cholesterol, HDL cholesterol, LDL cho-
lesterol, VLDL cholesterol, and leptin. In addition, fasting triacyl-
glycerol, fatty acids, glycerol, and total cholesterol were measured on
day 14. We also obtained blood samples to be analyzed for L-796568
concentration on day 0 and before the dose of L-796568 on days 21,
25, and 28; subjects were fasting when the blood was drawn.
A 24-h urine sample was collected for measurement of nitro-
gen and catecholamines from 0900 on day 0 to 0900 on day 1 and
again from 0900 on day 27 to 0900 on day 28. In addition, urine
was collected on day 1 from 0900 to 1500.
Blood and urine analyses
For the analyses of plasma glycerol and fatty acid concentra-
tions, 2 mL blood was drawn into a tube containing EDTA, kept
on ice, and centrifuged within 1 h at 1200  g for 15 min at 4 C;
the plasma was stored at 70 C until analyzed. The analysis was
done with an automated spectrophotometric procedure (19). For
the analyses of serum leptin, 4 mL blood was drawn into a tube,
kept on ice, and centrifuged within 1 h at 1200  g for 15 min at
20 C. The serum was stored at 70 C until analyzed with the
DSL-23100 leptin immunoradiometric assay kit (Diagnostic Sys-
tems Laboratories, Webster, TX).
For the analyses of plasma catecholamines, 6 mL blood was
drawn and immediately transferred into a fresh solution of
reduced glutathione; this was centrifuged at 806  g for 10 min
at 4 C. The plasma was immediately frozen in liquid nitrogen
and stored at 70 C until analyzed by using HPLC with elec-
trochemical detection (20). For the analyses of plasma L-796568,
5 mL blood was drawn into a tube containing heparin, placed
on ice, and centrifuged at 1670  g for 15 min at 4 C. The
plasma was stored at 20 C until analyzed by using solid-liq-
uid extraction, electrospray liquid chromatography–tandem
mass spectrophotometry (LC-MS/MS) method (Merck & Co,
West Point, PA).
For the analyses of serum or plasma lipids, 4 mL blood was drawn
into a tube, centrifuged at 2000  g for 10 min at 4 C, and kept at
18 C until analyzed. At the Copenhagen site, we measured serum
triacylglycerols with an enzymatic method (21) and serum HDL
cholesterol with an enzymatic method (22); serum LDL cholesterol
was calculated (23). At the Maastricht site, serum triacylglycerols
and serum total cholesterol were measured with an enzymatic
method (24), plasma HDL cholesterol was measured with an enzy-
matic method (25), and plasma LDL cholesterol was calculated (23).
For the analyses of -hydroxybutyrate and lactate, at the
Copenhagen site 5 mL blood was drawn into a tube containing
EDTA and mixed, 4 mL ice-cold perchloric acid was added, and
the solution was kept at 18 C until analyzed. -hydroxybutyrate
concentration was analyzed with a colorimetric method (Boehringer
Mannheim, Mannheim, Germany), and blood lactate was meas-
ured with enzymatic determination (26). At the Maastricht site,
serum -hydroxybutyrate was analyzed with an enzymatic method
(27) automated on a Cobas Fara centrifugal analyzer (Roche,
Basel, Switzerland). Plasma lactate was analyzed via enzymatic
determination (YSI model 2300 glucose and lactate analyzer; Yel-
low Springs Instruments Inc, Yellow Springs, OH).
Subjects underwent a 120-min oral-glucose-tolerance test
(OGTT) with 75 g glucose on 2 occasions: within the 7 d before the
study and on day 28 (the end of the study). Both OGTTs were per-
formed in the fasting state, but on day 28 the glucose was consumed
with 375 mg L-796568. For the analyses of glucose and insulin con-
centrations, at the Copenhagen site 4 mL blood was drawn into a gel
tube, allowed to coagulate, and centrifuged at 2000  g for 10 min
at 4 C. The serum was kept at 18 C until analyzed. Serum insulin
was measured with a radioimmunoassay kit from Pharmacia AS,
Copenhagen and serum glucose was measured with enzymatic glu-
cose oxidase (21). At the Maastricht site, serum insulin was analyzed
with an Autodelfia fluoroimmunoassay kit from Perkin-Elmer Wal-
lac Inc, Oy, Finland, and plasma glucose was measured with an
enzymatic method (28). For the analyses of plasma glucagon, at the
Copenhagen site 5 mL blood was drawn into a tube containing
EDTA, stored at 4 C for < 30 min, and centrifuged at 2000  g
for 10 min at 4 C. The plasma layer was transferred into a glass tube
holding 1.500 kallikrein-inactivating units (KIE) of Trasylol (Bayer
Pharma, Lyngby, Denmark). The sample was stored at 25 C until
analyzed with a radioimmunoassay kit from Diagnostic Products
Corp, Los Angeles. At the Maastricht site, serum glucagon was ana-
lyzed with a radioimmunoassay kit (glucagon double antibody; DPC
Biermann GmbH, Bad Nauheim, Germany).
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TABLE 1
Anthropometric and cardiovascular measures at baseline and energy
expenditure (EE) and nonprotein respiratory quotient (RQnp) during the
baseline stay in the respiration chamber1
Placebo group L-796568 group
(n = 10) (n = 10)
Age (y) 35 ± 8 37 ± 6
Height (cm) 184 ± 8 181 ± 5
Body weight (kg) 102.7 ± 12.7 103.5 ± 7.9
BMI (kg/m2) 30.3 ± 2.2 31.5 ± 2.1
Fat-free mass (kg)2 74.9 ± 10.7 70.9 ± 4.6
Fat mass (kg)2 28.7 ± 5.2 31.7 ± 5.0
Systolic BP (mm Hg) 128 ± 7 126 ± 6
Diastolic BP (mm Hg) 76 ± 9 81 ± 7
Heart rate (beats/min) 63 ± 6 63 ± 11
24-h EE (kJ/min) 8.13 ± 0.93 8.10 ± 0.45
24-h RQnp 0.846 ± 0.021 0.858 ± 0.020
Sleeping EE (kJ/min) 6.03 ± 0.93 5.92 ± 0.33
Basal metabolic rate (kJ/min) 7.48 ± 1.14 7.05 ± 0.73
Daytime RQnp 0.806 ± 0.028 0.838 ± 0.0353
1 x– ± SD. BP, blood pressure.
2 Determined within the 7 d before the baseline stay in the respiration
chamber.
3 Significantly different from the placebo group, P = 0.04.
TABLE 3
Changes from day 0 (baseline) to day 28 (day 28 value minus day 0 value)
for body weight, body composition, and cardiovascular measures1
Placebo group L-796568 group
(n = 10) (n = 10)
Body weight (kg) 0.2 ± 1.2 0.5 ± 1.6
Fat-free mass (kg)2 1.7 ± 2.8 0.4 ± 2.0
Fat mass (kg)2 1.0 ± 2.6 0.2 ± 1.5
Fat mass:fat-free mass2 0.02 ± 0.05 0.00 ± 0.03
Systolic BP (mm Hg) 5 ± 8 3 ± 11
Diastolic BP (mm Hg) 3 ± 5 2 ± 6
Heart rate (beats/min) 2 ± 5 3 ± 13
1 x– ± SD. BP, blood pressure. There were no significant differences
between the 2 groups in the magnitude of the change from day 0 to day 28.
2 Determined within the 7 d before the baseline stay in the respiration
chamber.
For the analyses of urinary nitrogen, urine was collected in
bottles containing 10 mL sulfuric acid (2 mol/L); 8 mL was
transferred into scintillation vials and stored at 20 C before
analysis via oxidative decomposition with heat conductance
detection (Heraeus CHN-O-RAPID; Heraeus GmbH, Hanau,
Germany). For the analyses of urinary norepinephrine and
epinephrine, 3 mL acidified urine was stored at 70 C before
analysis via HPLC with electrochemical detection (20).
Appetite profiles
Subjects were asked to complete appetite questionnaires dur-
ing both stays in the respiration chamber (29). The questionnaires
include questions related to hunger and satiety, both of which were
rated on a 100-mm visual analogue scale. Subjects recorded their
responses before lunch (while fasting), every hour for the 3 h after
lunch, before dinner, and every hour for the 3 h after dinner (a total
of 8 times).
Statistical analyses
The effect of treatment with L-796568 on 24-h EE was the pri-
mary endpoint of this study. Within each treatment group, changes
over time relative to baseline were tested by using a paired t test.
Mean (± SD) changes over time (eg, from day 0 to day 27) were cal-
culated and group differences were tested by using a two-sample
unpaired t test. If the group differences were significant or nearly
significant (P < 0.10) at baseline, group differences from day 0 to day
27 were recalculated with a general linear model univariate analysis
with baseline values added as cofactors. Changes in OGTT response
were tested with a general linear model on the basis of a repeated-
measures analysis of variance model, and significant group-by-time
interaction effects were subsequently analyzed with an unpaired t test.
Correlations were determined by using simple correlation analysis.
Because body weight and FFM were stable throughout the treatment
periods, these factors were not included in the analyses. Analyses
were performed with SPSS 10.0 for Windows (SPSS Inc, Chicago).
P < 0.05 was regarded as statistically significant.
RESULTS
All subjects completed the study in accordance with our proto-
col. The 2 groups were well matched with regard to anthropo-
metric and indirect calorimetry measures at baseline (Table 1).
There were no significant differences at baseline between the
groups in biochemical variables, except for triacylglycerol and
lactate, which were significantly higher (P < 0.05) in subjects
allocated to the L-796568 treatment. There was also a tendency
(P < 0.10) for higher total cholesterol and fatty acid concentra-
tions in the L-796568 group (Table 2).
In both groups, there were no significant changes in body weight,
body composition, heart rate, or blood pressure from day 0 to day 28.
The magnitude of the changes in these variables from day 0 to day
28 did not differ significantly between groups (Table 3).
TABLE 2
Blood and urine variables at baseline1
Placebo group L-796568 group
(n = 10) (n = 10)
Blood
Glucose (mmol/L) 5.35 ± 0.67 5.46 ± 0.52
Insulin (pmol/L) 64 ± 28 87 ± 56
Glucagon (pmol/L) 19 ± 5 26 ± 13
Fatty acids (mol/L) 324 ± 93 415 ± 1222
Glycerol (mol/L) 45 ± 12 58 ± 21
Triacylglycerols (mmol/L) 1.23 ± 0.64 2.03 ± 0.893
Lactate (mol/L) 720 ± 210 913 ± 1803
Ketones (mol/L) 87.7 ± 79.5 115.7 ± 73.6
Leptin (ng/mL) 11 ± 5 14 ± 10
Norepinephrine (nmol/L) 2.45 ± 1.40 2.00 ± 0.82
Epinephrine (pmol/L) 156 ± 80 147 ± 84
Total cholesterol (mmol/L) 4.9 ± 0.8 5.7 ± 1.22
HDL cholesterol (mmol/L) 1.1 ± 0.3 1.0 ± 0.2
LDL cholesterol (mmol/L) 3.2 ± 0.8 3.6 ± 1.0
Urine
Norepinephrine (g/24 h) 47.4 ± 13.3 56.5 ± 39.2
Epinephrine (g/24 h) 6.77 ± 2.44 6.94 ± 3.25
1 x– ± SD.
2 Tendency toward group difference, P < 0.10.
3 Significantly different from placebo group, P < 0.05.
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TABLE 4
Changes from day 0 (baseline) to day 27 (day 27 value minus day 0 value)
for energy expenditure (EE) and nonprotein respiratory quotient (RQnp)1
Placebo group L-796568 group
(n = 10) (n = 10)
24-h EE (kJ/min) 0.06 ± 0.36 0.06 ± 0.41
Sleeping EE (kJ/min) 0.01 ± 0.44 0.15 ± 0.32
Basal metabolic rate (kJ/min) 0.14 ± 0.60 0.14 ± 0.62
Daytime EE (kJ/min) 0.17 ± 0.40 0.03 ± 0.44
Postdinner EE (kJ/min) 0.10 ± 0.48 0.16 ± 0.86
Exercise EE (kJ/min)2 3.49 ± 5.64 0.52 ± 1.60
24-h RQnp 0.029 ± 0.021 0.009 ± 0.029
Sleeping RQnp 0.046 ± 0.041 0.041 ± 0.037
Basal RQnp 0.067 ± 0.039 0.044 ± 0.050
Daytime RQnp3 0.044 ± 0.031 0.001 ± 0.040
Postdinner RQnp 0.025 ± 0.031 0.029 ± 0.063
Exercise RQnp 0.027 ± 0.077 0.045 ± 0.056
1 x– ± SD.
2 Exercise value was measured during a 15-min session of cycling
(1430–1445).
3 Without the cofactor, P < 0.02 for the difference between the 2 groups
in the magnitude of change from day 0 to day 27. With the baseline value
as a cofactor, P = 0.15.
FIGURE 1. Acute effect (A): change in daytime nonprotein respiratory quotient (RQnp) between day 0 (baseline) and day 1 (measured from 0
to 4 h postdose). There was a significant between-group difference without correction for baseline values (P < 0.02); however, when baseline data
were included as a cofactor the difference was not significant (P = 0.21). Chronic effect (B): change in 24-h RQnp between day 0 and day 27
(P = 0.09). n = 10 per group.
FIGURE 2. Correlation between mean predose plasma L-796568 con-
centration on days 21, 25, and 28 and change in fat mass from pretreat-
ment to posttreatment (r = 0.69, P < 0.03); n = 10. Each  represents the
mean L-796568 concentration for 1 subject on the 3 measurement days.
When we compared day 0 with day 1 to test for an acute
effect, we observed no between-group differences in daytime
EE (0.37 ± 0.47 and 0.41 ± 0.58 kJ/min for the placebo and
L-796568 groups, respectively), but there was a significantly
smaller increase (P < 0.02) in daytime nonprotein respiratory
quotient (RQnp) in the L-796568 group (0.025 ± 0.041) than in
the placebo group (0.064 ± 0.021) (Figure 1). However, the dif-
ference was not significant (P = 0.21) when the higher baseline
RQnp values for the L-796568 group were included as a cofac-
tor in the analysis. The same tendency was observed for RQnp
during exercise, although the difference was not significant
(0.000 ± 0.040 and 0.039 ± 0.055 for the placebo and L-796568
groups, respectively).
For all the time intervals (ie, 24 h, sleep, daytime, postdinner,
during exercise, and basal metabolic rate), changes in EE and
RQnp from day 0 to day 27 were not significantly different
between the 2 groups (with or without adjustment for changes in
FFM and energy balance), except for a significantly smaller
increase in daytime RQnp in the L-796568 group (unadjusted for
energy balance; 0.044 ± 0.031 and 0.001 ± 0.040 in the placebo
and L-796568 groups, respectively; P < 0.02) (Table 4). However,
this significant difference in daytime RQnp for the chronic
response was no longer significant (P = 0.15) when the higher
baseline RQnp values for the L-796568 group were included as a
cofactor in the analysis.
Compliance was assured by observation of daily dosing and by
measurement of the mean predose plasma L-796568 concentra-
tions on days 21, 25, and 28 (3-d mean ± SD = 77.2 ± 30.3 nmol/L);
these values were as predicted on the basis of previous studies.
Even though there was no overall difference between groups in
the body composition variables, there was a significant inverse
correlation between the change in fat mass (poststudy minus
prestudy) and the average predose plasma L-796568 concentra-
tion in the L-796568 group (r = –0.69, P < 0.03), ie, higher
L-796568 concentrations were associated with greater decreases
in fat mass (Figure 2). The decreases in fat mass were small,
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FIGURE 4. Glucose and insulin responses during oral-glucose-tolerance tests (OGTTs) performed pretreatment () and on day 28 (); n = 10 per
group. No significant changes were found in the incremental area under the curve, but there was a significant time  day  group interaction effect
(P < 0.02; general linear model for repeated-measures ANOVA) for glucose, with higher serum glucose at 120 min in the L-796568 group than in the
placebo group on day 28 (P < 0.03).
FIGURE 3. Correlation between mean predose plasma L-796568 con-
centration on days 21, 25, and 28 and change in fat-free mass from pre-
treatment to posttreatment (r = 0.21, P = 0.56); n = 10. Each  represents
the mean L-796568 concentration for 1 subject on the 3 measurement days.
however. No significant correlations were found between
plasma L-796568 concentration and changes in FFM (Figure 3)
or other endpoints, including changes in 24-h EE (r = 0.08,
P = 0.98), 24-h RQnp (r = 0.56, P = 0.09), and the ratio of fat mass
to FFM (r = 0.52, P = 0.13).
The results of the OGTTs showed no significant differences
between the treatment groups in the changes in the incremen-
tal areas under the curve for plasma glucose, insulin, or
glucagon responses. However, a time  day  group interac-
tion effect was found (P < 0.02) for the glucose response, and
subsequent unpaired t test analysis at each time point showed
a significantly higher glucose concentration at the 120-min
time point in the L-796568 group than in the placebo group on
day 28 (P < 0.03) (Figure 4).
On day 14, fasting triacylglycerol, total cholesterol, and fatty
acid concentrations were significantly decreased in the L-796568
group compared with the placebo group, but only the decrease
in total cholesterol was significant when baseline values were
included as a covariate (P < 0.005) (data not shown). There
were no significant differences in the changes in glycerol
between the groups.
For triacylglycerol and total cholesterol, there were signifi-
cant decreases in the L-796568 group compared with the
placebo group from baseline (day 0) to day 28 (Table 5). When
the higher baseline values of the L-796568 group were taken
into account, only the change in triacylglycerol remained signi-
ficantly different between the groups (0.76 ± 0.76 and
0.42 ± 0.31 mmol/L for the L-796568 and placebo groups,
respectively; P < 0.002).
We found no significant differences between groups for
blood concentrations of LDL cholesterol, HDL cholesterol,
ketones, lactate, leptin, norepinephrine, or epinephrine, or for
urinary nitrogen or catecholamine excretion. The 2 groups did
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TABLE 5
Changes in blood lipids from day 0 (baseline) to days 14 and 28
P1
Placebo group (n = 10) L-796568 group (n = 10) No cofactor With cofactor
Fatty acids (mol/L)
Day 14  day 0 14 ± 312 11 ± 11 <0.03 0.07
Day 28  day 0 17 ± 128 8 ± 215 0.91 —
Glycerol (mol/L)
Day 14  day 0 21 ± 50 5 ± 19 0.34 —
Day 28  day 0 4 ± 15 6 ± 19 0.81 —
Triacylglycerols (mmol/L)
Day 14  day 0 0.19 ± 0.55 0.84 ± 0.88 <0.01 0.13
Day 28  day 0 0.42 ± 0.31 0.76 ± 0.76 <0.001 <0.002
Total cholesterol (mmol/L)
Day 14  day 0 0.2 ± 0.5 0.8 ± 0.6 <0.002 <0.005
Day 28  day 0 0.1 ± 0.7 0.7 ± 0.6 <0.02 0.07
1 P values are for differences between groups (unpaired t test); the cofactor was the baseline value.
2 x– ± SD.
not differ significantly with regard to hunger or satiety ratings
at lunch or dinner.
Nine subjects in the L-796568 group and 2 in the placebo group
reported gastrointestinal side effects, primarily diarrhea, during the
treatment period. No subjects reported tremor (data not shown).
DISCUSSION
Previous pharmacologic studies have used a variety of
approaches to try to elucidate the thermogenic potential of 3
receptors in humans, but these studies have reported conflicting
results. One approach has been to study EE with nonspecific 
agonists in the presence of 1 and 2 antagonists to isolate any
effects caused by 3 agonist stimulation. In one study, 43% of the
thermogenic effect of ephedrine (which potentiates the synaptic
release of noradrenaline) remained after pretreatment with the 1
and 2 antagonist nadolol (30). Other studies showed that isopre-
naline and BRL35135 (nonspecific 3 agonists) have thermogenic
effects that are not completely abolished by nadolol (31, 32).
However, these findings were not confirmed in other studies that
used a similar approach (33, 34). A second approach has been to
investigate the effect of putative 3 agonists. Of all the previous
studies on this topic, the one that seems the most informative eval-
uated the effect of the 3 agonist CL316 243, at a dose of 1500
mg/d, on EE and RQ (10). CL316 243 is a partial but selective
human 3 agonist (60% activity compared with isoprenaline;
> 1500-fold selectivity over 1 and 2) (35), but is 1000-fold
less potent (EC50 = 3700 nmol/L) than is L-796568 (K Gottesdi-
ener and Merck & Co, unpublished observations, 1999). Plasma
concentrations in the study were low compared with its EC50
value, and CL316 243 failed to increase EE after 8 wk of chronic
administration.
In the present study of obese subjects, 375 mg of the human
3-adrenergic receptor agonist L-796568, taken once daily, had
no effect on 24-h EE or on EE during any other time interval, nei-
ther acutely nor after 28 d of administration. These results were
surprising, because an acute 8% increase in EE was observed after
administration of a single 1000-mg dose of L-796568 to obese
subjects who had fasted overnight (13). The lack of acute effect
on EE on the first treatment day in this study was less surprising,
because the present study had a different design in which subjects
were not resting and were served a large breakfast during the
measurements; these factors are both likely to increase variability.
One explanation for the lack of chronic effect of L-796568 on
EE could be that the plasma concentrations were too low. Overall,
we think this is unlikely for the following reasons: 1) L-796568 is
a very potent (EC50 3.6 nmol/L) and full agonist of the human
3-adrenergic receptor and average plasma concentrations were
77 nmol/L, or > 20-fold higher than EC50 values, throughout the
day; 2) lower plasma concentrations were associated with signifi-
cant increases in EE in the rhesus monkey (K Gottesdiener and
Merck & Co, unpublished observations, 1999); and 3) in a separate
study, this dosing regimen (375 mg with food) resulted in peak
plasma concentrations of 175 nmol/L, which is well above the
peak plasma concentrations (100 nmol/L) achieved in the acute
study that led to an 8% increase in EE (13).
An alternative explanation for the lack of chronic effect on EE
might be that the agonist- induced BAT proliferative capability of
3 receptor–responsive tissues in humans was too low during
chronic stimulation. BAT, the primary tissue that responds to 3
stimulation in rodents and possibly in rhesus monkeys, is only
present in very limited amounts in adult humans and has ques-
tionable functional capacity. Thus, an acute 3-stimulated
increase in EE in humans is less likely to be dependent on BAT
and might be mediated directly by WAT and perhaps indirectly
by the liver and muscles. This is consistent with studies in trans-
genic mice that showed that the major part of acute 3-agonist-
induced thermogenesis and lipolysis is mediated by WAT and not
by BAT (36). Compared with 1 and 2 receptors, 3 receptors
have quite low expression in human WAT (37), yet seem capable
of producing an acute increase in EE. In addition, BAT might be
up-regulated after chronic 3 receptor stimulation. One study
showed that 28 d of treatment with the 3 adrenergic receptor
agonist L-755507 was sufficient to induce significant BAT pro-
liferation and uncoupling protein 1 up-regulation in rhesus mon-
keys (12). If humans are similar to rhesus monkeys in this
respect, this 28-d study might have led to BAT proliferation,
uncoupling protein 1 up-regulation, and increases in EE that
exceeded the acute effects.
Another likely explanation for the lack of chronic effect on EE
is down-regulation of 3 receptors, even though previous in vivo
studies in rodents showed no signs of 3-adrenergic receptor
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agonist–induced down-regulation (38, 39). If down-regulation is
the cause of the lack of chronic 3-adrenergic receptor–mediated
thermogenesis, this suggests that a different 3-adrenergic recep-
tor–desensitizing mechanism occurs in humans. However, we also
cannot rule out the possibility that some type of negative feedback
occurs, possibly via inhibition of lipolysis with indirect effects on
EE. Studies in humans showed increased thermogenesis during
intravenous infusions of lipid plus heparin (ie, increased fatty
acids) (40), suggesting that mobilization of fatty acids may be the
major determinant of 3-agonist-induced thermogenesis. How-
ever, an attenuated response of 3 agonist-mediated increases in
plasma fatty acid concentrations was observed after 9 d of treat-
ment with 375 mg L-796568 in healthy volunteers; the acute
increases measured on the first treatment day were completely
absent after 9 d of treatment (K Gottesdiener and Merck & Co,
unpublished observations, 1999).
Interestingly, however, we did not find any 3 agonist–induced
changes in catecholamine concentrations or excretion, suggesting
that there was no major influence on lipolysis via changes in
endogenous catecholamine metabolism. The lack of effect of the
agonist under conditions when food intake is not altered does not
exclude the possibility that the drug may show thermogenic effi-
cacy in preventing the fall in EE under conditions of hypocaloric
dieting, ie, when sympathetic activity is low and there is a ten-
dency for adrenergic receptors to be up-regulated.
In the present weight-maintenance study, FFM and fat mass did
not differ significantly between groups. However, the observed
changes in body fat mass in the L-796568 group were inversely
correlated with plasma L-796568 concentrations measured at the
end of the study period, suggesting sustained increased fat oxida-
tion. After 28 d of treatment, there was no sustained increase in
the mobilization of fatty acids, as assessed by measuring fasting
concentrations of fatty acids and glycerol.
When baseline RQnp values were included as a cofactor in the
analysis, there was no significant effect of L-796568 on substrate
partitioning represented by RQ or nonprotein RQ, but regarding
acute induced thermogenesis, any acute effect on daytime RQnp
may be masked by interference induced by diet and physical activ-
ity. However, among all the measuring periods, daytime RQnp
shows the largest decrease and thus indicates an acute stimulatory
effect of a drug on fat oxidation, which may be dependent on fatty
acid mobilization. On the contrary, we did not find a significant
chronic effect on substrate partitioning, as indicated by the lack
of effect on 24-h RQnp (Figure 1).
Treatment with L-796568 reduced plasma triacylglycerol and
total cholesterol concentrations to a greater extent than did
placebo after 14 d. In L-796568 studies conducted in dogs and
monkeys, decreased triacylglycerol concentrations were also
found (K Gottesdiener and Merck & Co, unpublished observa-
tions, 1999), and chronically decreased triacylglycerol concentra-
tions were observed previously in selective 3 agonist studies in
obese mice (41). 3 agonists were shown to improve glucose tol-
erance in humans (10, 42), but in this study, we found no signifi-
cant effect of L-796568 on glucose tolerance. The plasma glucose
profile over time in the L-796568 group shows lower and more
sustained concentrations, which may have been caused by
decreased gastric emptying resulting from the known effects of 3
agents on gastric motility (43–45).
There was no evidence in this study that L-796568 had effects
on 1 and 2 receptors, as indicated by the absence of tachycardia,
tremor, and increased blood pressure and the lack of effects on
plasma potassium. Significantly more subjects in the L-796568
group had gastrointestinal side effects such as diarrhea, an effect
which was previously found in dogs (K Gottesdiener and Merck
& Co, unpublished observations, 1999) but not in human studies
of CL316 243 (C Weyer, personal communication, 2001). In ani-
mal models, 3 agonists had anorectic effects, but L-796568 did
not seem to have any effect on appetite parameters assessed dur-
ing the subjects’ stays in the respiration chamber.
In conclusion, no chronic thermogenic effect of L-796568 was
found in obese, nondiabetic young men. There was also no evi-
dence of stimulation of fat oxidation by L-796568, although
changes in fat mass correlated negatively with drug concentra-
tions, suggesting some potential activity at the 3 receptor. In
addition, triacylglycerol concentrations decreased substantially in
the L-796568 group. In contrast with most studies of nonspecific
3 agonists, there was no evidence of 1 or 2 stimulation to con-
found these results. The lack of chronic effects most likely
resulted from down-regulation of 3 effects (indirectly or directly
via down-regulation of receptors) or a lack of recruitment of BAT
in humans, or both.
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